FDA 批准 Akebia Therapeutics 的口服贫血治疗药物 Vafseo 用于治疗慢性肾病透析患者。 FDA approves Akebia Therapeutics' oral anemia treatment Vafseo for chronic kidney disease patients on dialysis.
FDA 已批准 Akebia Therapeutics 的 Vafseo (vadadustat) 片剂用于治疗接受透析至少三个月的慢性肾病 (CKD) 成年患者的贫血症。 The FDA has approved Akebia Therapeutics' Vafseo (vadadustat) tablets for treating anemia in adult patients with chronic kidney disease (CKD) who have been on dialysis for at least three months. Vafseo 是一种口服缺氧诱导因子脯氨酰羟化酶 (HIF-PH) 抑制剂，是治疗这种疾病的第一个口服治疗药物，已在包括美国在内的 37 个国家获得批准。 Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first oral treatment for this condition, approved in 37 countries including the US. Akebia Therapeutics 计划与其合作伙伴 CSL Vifor 在美国将 Vafseo 商业化，CSL Vifor 拥有向费森尤斯肾脏护理透析中心和其他第三方透析组织销售该药物的独家许可。 Akebia Therapeutics plans to commercialize Vafseo in the US with its partner CSL Vifor, which has an exclusive license to sell the drug to Fresenius Kidney Care dialysis centers and other third-party dialysis organizations.